Compare AbCellera Biologics Inc (ABCL) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

SOXL, a 3x leveraged semiconductor ETF, trades at $194.65, up 7.26% in 24 hours but remains in a bearish technical trend. Recent volatility includes a 16% single-day drop on July 1, 2026 (24/7 Wall Street), highlighting risks of leveraged decay. News sentiment is mixed, with JPMorgan advocating buying the chip dip while Morgan Stanley notes investor rotation away from semiconductors. Key support lies at $189, with resistance at $200.

Outlook is highly speculative due to leverage amplifying sector swings. Opportunities exist for tactical traders betting on semiconductor rebounds, but risks of rapid decay in choppy markets are severe. Long-term holders face structural erosion from volatility, making SOXL unsuitable for buy-and-hold strategies amid elevated sector uncertainty.